Hepatitis-Associated Aplastic Anemia

Authors

Alfadel Alshaibani, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi ArabiaFollow
Carlo Dufour, Hematology-Oncology-HSCT Pole, G.Gaslini IRCCS Children Hospital, Genova, ItalyFollow
Antonio Risitano, Department of Clinical Medicine and Surgery, Bone Marrow Transplant Center, Federico II University of Naples, Naples, ItalyFollow
Regis de Latour, Saint Louis Hospital, Paris Diderot University, Paris, FranceFollow
Mahmoud Aljurf, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi ArabiaFollow

Abstract

Hepatitis-associated aplastic anemia (HAAA) is a rare illness, characterized by onset of pancytopenia with a hypoplastic bone marrow that traditionally occurs within 6 months of an increase in serum aminotransferases. HAAA is observed in 1% to 5% of all newly diagnosed cases of acquired aplastic anemia. Several hepatitis viruses have been linked to the disease, but in many cases no specific virus is detected. The exact pathophysiology is unknown; however, immune destruction of hematopoietic stem cells is believed to be the underlying mechanism. HAAA is a potentially lethal disease if left untreated. Management includes immunosuppression with antithymocyte globulin and cyclosporine and allogeneic hematopoietic stem cell transplantation.

Recommended Citation

Alshaibani, Alfadel; Dufour, Carlo; Risitano, Antonio; de Latour, Regis; and Aljurf, Mahmoud (2022) "Hepatitis-Associated Aplastic Anemia," Hematology/Oncology and Stem Cell Therapy: Vol. 15 : Iss. 2 , Article 2.
Available at: https://doi.org/10.1016/j.hemonc.2020.10.001

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.